Proof-of-Concept and Safety of the Anti-FcRn Antibody Rozanolixizumab in Patients with Moderate-to-Severe Generalized Myasthenia Gravis (GMG): A Phase 2a Study

被引：0
|
作者：
Bril, Vera [1 ,2 ,3 ]
Benatar, Michael [4 ]
Brock, Melissa [5 ]
Greve, Bernhard [5 ]
Kiessling, Peter [5 ]
Woltering, Franz [5 ]
Van den Bergh, Peter [6 ]
机构：
[1] Toronto Gen Hosp, Ellen & Martin Prosserman Ctr Neuromuscular Dis, Toronto, ON, Canada
[2] Univ Toronto, Div Neurol, Toronto, ON, Canada
[3] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat, Dammam, Saudi Arabia
[4] Univ Miami, Miami, FL USA
[5] UCB Pharma, Raleigh, NC USA
[6] Univ Louvain, Univ Hosp St Luc, Dept Neurol, Neuromuscular Reference Ctr, Brussels, Belgium
来源：
NEUROLOGY | 2019年 / 92卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S43.001
引用
收藏
页数：3
相关论文
共 50 条
  • [21] The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results
    Feagan, B. G.
    Sands, B.
    Siegel, C. A.
    Dubinsky, M.
    Longman, R.
    Sabinho, J.
    Laurent, O.
    Luo, A.
    Lu, J. D.
    Nguyen, D.
    Towfic, F.
    DuVall, A.
    Woyranowski, M.
    Al Kharrat, H.
    McGovern, D. P. B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : I162 - I164
  • [22] The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results
    Feagan, Brian G.
    Sands, Bruce E.
    Siegel, Corey A.
    Dubinsky, Marla C.
    Longman, Randy
    Sabino, Joao
    Laurent, Olivier
    Luo, Allison
    Lu, J. D.
    Nguyen, Deanna D.
    Towfic, Fadi
    DuVall, Aaron
    Woynarowski, Marek
    Al Kharrat, Houssam
    McGovern, Dermot
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S875 - S876
  • [23] Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial
    Alavi, Afsaneh
    Prens, Errol P.
    Kimball, Alexa B.
    Frew, John W.
    Krueger, James G.
    Mukhopadhyay, Sutirtha
    Gao, Heli
    Ranganathan, Usha
    Ivanoff, Nathalie B.
    Hernandez Daly, Ana C.
    Zouboulis, Christos C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 (04) : 508 - 518
  • [24] Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study
    Sands, Bruce E.
    Chen, Jingjing
    Feagan, Brian G.
    Penney, Mark
    Rees, William A.
    Danese, Silvio
    Higgins, Peter D. R.
    Newbold, Paul
    Faggioni, Raffaella
    Patra, Kaushik
    Li, Jing
    Klekotka, Paul
    Morehouse, Chris
    Pulkstenis, Erik
    Drappa, Jorn
    van der Merwe, Rene
    Gasser, Robert A., Jr.
    [J]. GASTROENTEROLOGY, 2017, 153 (01) : 77 - +
  • [25] IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study
    Kimball, Alexa B.
    Loesche, Christian
    Prens, Errol P.
    Bechara, Falk G.
    Weisman, Jamie
    Rozenberg, Izabela
    Jarvis, Philip
    Peters, Thomas
    Roth, Lukas
    Wieczorek, Grazyna
    Kolbinger, Frank
    Jemec, Gregor B. E.
    [J]. EXPERIMENTAL DERMATOLOGY, 2022, 31 (10) : 1522 - 1532
  • [26] EFFICACY AND SAFETY OF ANTI-INTERLEUKIN-23 THERAPY WITH MIRIKIZUMAB (LY3074828) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS IN A PHASE 2 STUDY
    Sandborn, William J.
    Ferrante, Marc
    Bhandari, Bal R.
    D'Haens, Geert R.
    Berliba, Elina
    Feagan, Brian G.
    Laskowski, Janelle
    Friedrich, Stuart
    Durante, Michael
    Tuttle, Jay
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S1360 - S1361
  • [27] A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata
    Daniela Mikhaylov
    Jacob W. Glickman
    Ester Del Duca
    John Nia
    Peter Hashim
    Giselle K. Singer
    Alba L. Posligua
    Aleksandra G. Florek
    Erin Ibler
    Erika L. Hagstrom
    Yeriel Estrada
    Stephanie M. Rangel
    Maria Colavincenzo
    Amy S. Paller
    Emma Guttman-Yassky
    [J]. Archives of Dermatological Research, 2023, 315 : 181 - 189
  • [28] A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata
    Mikhaylov, Daniela
    Glickman, Jacob W.
    Del Duca, Ester
    Nia, John
    Hashim, Peter
    Singer, Giselle K.
    Posligua, Alba L.
    Florek, Aleksandra G.
    Ibler, Erin
    Hagstrom, Erika L.
    Estrada, Yeriel
    Rangel, Stephanie M.
    Colavincenzo, Maria
    Paller, Amy S.
    Guttman-Yassky, Emma
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2023, 315 (02) : 181 - 189
  • [29] First-in-class phase 2a study of anb020 (anti-il-33) in the treatment of moderate-to-severe atopic dermatitis
    Chen, Y.
    Gutowska-Owsiak, D.
    Westmoreland, M.
    Mackenzie, T.
    Cifuentes, L.
    Lloyd-Lavery, A.
    Marquette, A.
    Kenney, B.
    Londei, M.
    Ogg, G.
    [J]. ALLERGY, 2018, 73 : 77 - 77
  • [30] A Phase 2A, randomised, double-blind, placebo-controlled study to evaluate efficacy and safety of PF-06700841 in patients with moderate-to-severe plaque psoriasis
    Forman, S.
    Pariser, D. M.
    Poulin, Y.
    Vincent, M. S.
    Gilbert, S. A.
    Kieras, E. M.
    Qiu, R.
    Yu, D.
    Papacharalambous, J.
    Peeva, E.
    [J]. EXPERIMENTAL DERMATOLOGY, 2018, 27 : 37 - 37
12345